What is TSCIP?

Not desk-based diagnosis. Active buyer engagement.

TSCIP is a selective oncology transaction practice that takes admitted assets into the field—mapping the right pharma teams, engaging them directly, synthesizing de-identified decision requirements and using those outputs to move the asset toward transaction readiness.

A field-to-transaction loop.

The Tumor-State Combination Intelligence Platform combines a private asset intelligence layer with real-world BD execution. The platform preserves the asset history, strategic thesis and buyer context; field work tests that thesis with relevant S&E, External Innovation, BD and franchise teams.

The result is not merely a report describing what a hypothetical buyer might want. It is a transaction-readiness plan informed by actual, de-identified market engagement.

Core public model

Select → Map → Engage → Synthesize → Convene → Advance & Re-engage.

What TSCIP actively does.

Buyer-specific mappingIdentify the counterparties whose portfolio, strategy and development needs create a credible fit.
One-on-one field BDTake the asset thesis directly to relevant pharma teams rather than leaving outreach to the owner.
De-identified feedbackReturn evidence requirements, objections and decision conditions without exposing private buyer activity.
Qualified introductionsFacilitate direct buyer-owner interaction when the counterparty chooses to move beyond private review.
Strategic Asset ReviewsWhere warranted, convene a small buyer-specific slate of pre-vetted assets for focused owner presentations.
Re-engagementReturn to mapped buyers after the evidence, development plan or transaction proposition changes.

Selective admission protects buyer trust.

TSCIP cannot credibly promise active buyer engagement for every asset that wants to join. Coverage is selective and depends on whether there is a credible buyer universe, strategic fit, transactionable rights and a solvable path to greater readiness.

Joining TSCIP is not buying access. Direct meetings and Strategic Asset Review participation are qualification-driven and occur only when TSCIP field work and buyer review support a credible fit.

Confidentiality remains part of the product.

Buyer searches, views, saves, passes, named feedback and private company requirements are not disclosed to asset owners unless disclosure is authorized. TSCIP converts those interactions into de-identified owner-facing decision intelligence while keeping its internal scoring, counterparty-selection logic and evidence methodology proprietary.